DUBLIN, Apr. 16, 2015 /PRNewswire/ --Research and Markets

(http://www.researchandmarkets.com/research/kh5kqg/the_corporate) has announced the addition of the "The Corporate Reputation of Pharma - The Patient Perspective in 2014 - Global Edition " report to their offering.

The Corporate Reputation of Pharmafrom a Patient Perspective' is now in its fourth edition. This report contains the latest version (2014 results; published early 2015). For each annual Corporate Reputation report, the author surveys a large number of patient groups worldwideinternational, national, and regional, from across many different disease and healthcare specialties. 1,150 patient groups from 58 countries participated in the Corporate Reputation's 4th edition.

About the questionnaire:

The methodology for assessing pharma corporate reputation from a patient perspective was first established by PatientView in 2010 following consultations with pharma, medical-device companies, tradesbodies and patient groups. The resulting questionnaire combines the priorities of patient groups (which have a better understanding of pharma than individual patients) and industry on the topic of corporate reputation. The same questions on corporate reputation are posed to respondent patient groups every year (though each year's respondent patient groups are not necessarily the same as those of the previous year).

The answers help define what patients require from pharma companies, while acknowledging what pharma itself thinks it is capable of delivering. Since the questions do not deviate, the Corporate Reputation of Pharma allows the performance of individual pharma companies (and the industry as a whole) to be compared year on yearwhich, in turn, helps define appropriate strategies for improvement.

I was torn between ethical, transparency, and patient safety. But, ultimately, patient safety is the most important to me and to our organization Global, US-based patient group focusing on cancer and palliative care

Key Topics Covered:

1. Introduction
2. Understanding The Results
3. Methodology
4. Appendices:
5. Reputation of Pharma in 2014
6. Rankings of 37 Companies
7. Profiles of 37 Companies
8. Profile of Respondents

Companies Mentioned

- AbbVie
- Actavis
- Allergan
- Amgen
- Astellas
- AstraZeneca
- Baxter International
- Bayer
- Biogen Idec
- Boehringer- Ingelheim
- Bristol-Myers Squibb
- Celgene
- Eisai
- Eli Lilly
- GSK
- Gilead
- Grünenthal
- Ipsen
- Janssen
- Lundbeck
- Menarini
- Merck & Co
- Mylan
- Novartis
- Novo Nordisk
- Otsuka
- Pfizer
- Roche
- Sanofi
- Servier
- Shire
- Stada Arzneimittel
- Takeda
- Teva
- UCB

For more information visit http://www.researchandmarkets.com/research/kh5kqg/the_corporate

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

Related Links

http://www.researchandmarkets.com

SOURCE Research and Markets